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N-linked glycanMost lysosomal storage diseases are caused by defects in genes encoding for acidic hydrolases. Deﬁciency of
an enzyme involved in the catabolic pathway of N-linked glycans leads to the accumulation of the respec-
tive substrate and consequently to the onset of a speciﬁc storage disorder. Di-N-acetylchitobiase and core
speciﬁc α1–6mannosidase represent the only exception. In fact, to date no lysosomal disease has been cor-
related to the deﬁciency of these enzymes. We generated di-N-acetylchitobiase-deﬁcient mice by gene tar-
geting of the Ctbs gene in murine embryonic stem cells. Accumulation of Man2GlcNAc2 and Man3GlcNAc2
was evaluated in all analyzed tissues and the tetrasaccharide was detected in urines. Multilamellar inclusion
bodies reminiscent of polar lipids were present in epithelia of a scattered subset of proximal tubules in the
kidney. Less constantly, enlarged Kupffer cells were observed in liver, ﬁlled with phagocytic material resem-
bling partly digested red blood cells. These ﬁndings conﬁrm an important role for lysosomal di-N-
acetylchitobiase in glycans degradation and suggest that its deﬁciency could be the cause of a not yet de-
scribed lysosomal storage disease.
© 2012 Elsevier B.V. All rights reserved.1. Introduction
During the degradation of glycoproteins with asparagine-linked
carbohydrates, the N-acetylglucosamine residue at the reducing end
of the N,N′ diacetylchitobiose core of oligosaccharides is hydrolyzed
by the lysosomal glycosidase di-N-acetylchitobiase (chitobiase) (EC
3.2.1.-) [1]. This enzyme was ﬁrst puriﬁed and characterized in
human liver [2]; human and rat chitobiase cDNAs were cloned [3].
To date, no storage disease has been described in humans or ani-
mals as a result of chitobiase deﬁciency. However, cloning and char-
acterization of the human core-speciﬁc lysosomal α1–6mannosidase
(MAN2B2) demonstrated that this enzyme is dependent on chito-
biase activity [4–7] during the degradation of the Manα1–3
[Manα1–6]Manβ1–4GlcNAcβ1–4GlcNAc core structure resulting
from the catabolism of N-linked oligosaccharides (Fig. 1, panel A).E.E.A., Via San Costanzo, 06121
57904.
rights reserved.While lysosomal α-mannosidase (LysMan) can cleave the Manα1–3
from the non-reducing end of this structure, the efﬁcient removal of
Manα1–6 residue by α1–6mannosidase requires the trimming of
the reducing terminal GlcNAc by chitobiase. These data are conﬁrmed
by the accumulation of Manα1–6Manβ1–4GlcNAcβ1–4GlcNAc-Asn
in tissues of N-aspartylglucosaminidase-deﬁcient mice [8], a mouse
model for the lysosomal disorder aspartylglycosaminuria.
Chitobiase, as well as lysosomal α1–6mannosidase, is expressed
only in humans and rodents, whereas alterations in promoter sequence
inhibit its expression in ruminants, felines and dogs [9,10]. This differ-
ence could explain the variation in the glycan structures accumulated
in subjects affected by alpha-mannosidosis, a lysosomal storage disease
caused by the genetic deﬁciency of α-mannosidase, in various species.
In cattle, cats and dogs a deﬁciency of α-mannosidase causes the accu-
mulation of the tri-mannosyl core (Manα1–3[Manα1–6]Manβ1–4-
GlcNAcβ1–4GlcNAc) in addition to the extended structures on the
α1–3Man branch [11]. In humans and rodents the main stored struc-
ture is Manα1–3Manβ1–4GlcNAc, along with other extended products
on the α1–3Man branch [6,12,13].
The murine gene encoding the chitobiase (Ctbs) has been recently
cloned [14]. The gene spans about 15 kb from the transcription initi-
ation site to the translation stop codon and includes 7 exons, like
Fig. 1. Degradation of the N-linked glycan core and targeted disruption of Ctbs gene. (A) Stepwise trimming of the glycan core derived from N-linked oligosaccharides. The removal
of the terminal N-acetyl-glucosamine by chitobiase is essential for the core speciﬁc α1–6 mannosidase activity. (B) Schematic representation of the endogenous Ctbs gene, the tar-
geting construct and the disrupted allele. Boxes are the exons. Black parts indicate coding regions, white parts represent non-coding regions. The 5′ probe used for Southern blot is
indicated, as well as primers used to screen recombinant ES clones and mouse litters (F, R, N). Arrow within the NEO cassette indicates transcriptional orientation. (C) Southern blot
analysis of liver genomic DNA. EcoRI digested DNA of wild type (+/+), heterozygous (+/−) and KO (−/−) mice was separated on an agarose gel, blotted and hybridized with the
5’ probe. The 6.1 kb band corresponds to the wild type allele, the 5.0 kb band represents the mutant allele. (D) PCR genotyping of mouse tail DNA. Primers F, R and N were used in
the same reaction. 3.2 kb and 2.7 kb bands correspond to mutated and wild type allele, respectively. (E) RT-PCR of kidney RNA. RNA of wild type and CTBS deﬁcient mice was retro-
transcribed and PCR ampliﬁed. 1.2 kb band represents the main CTBS transcript, obtained with a primer forward on 5′ UTR and a primer reverse on 3′ UTR. 250 bp band corresponds
to a fragment of beta-actin cDNA, used as an internal control.
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human enzymes show 79% identity and 86% similarity.
In this study, we present the ﬁrst chitobiase-deﬁcient mouse
model. In order to disrupt the Ctbs gene, the open reading frame of
the neomycin resistance gene (NEO) was inserted in exon 2. RT
PCR, enzyme assay and Western blotting analyses conﬁrmed that no
detectable amount of chitobiase was expressed in chitobiase KO
mice. Although no overt phenotypical alteration is evident, signiﬁcant
amounts of the Man2GlcNAc2 tetrasaccharide and, to a minor extent,
of the Man3GlcNAc2 pentasaccharide accumulate in several KO tis-
sues. Histological analysis reveals typical features of other murine
models of lysosomal storage diseases: ﬁrstly and more evidently the
presence of multilamellar inclusion bodies indicative of polar lipids
in epithelial cells of scattered proximal kidney tubules, in addition
to enlarged vacuolated Kupffer cells. Preliminary data from lectin
screening indicate that mannosyl compounds may accumulate even
in those epithelial cells that are still devoid of ultrastructurally visible
storage material.
The accumulation of oligosaccharides and the pathological fea-
tures observed in this mouse model provide the ﬁrst in vivo evidence
of the crucial role of chitobiase in glycans degradation. Since the role
of chitobiase is the same in mice and humans, this result suggests that
the genetic lack of chitobiase could be the cause of a not yet described
human lysosomal storage disease.2. Materials and methods
2.1. Construction of the targeting vector
A 5.4 kb XbaI fragment obtained from the Mouse Genomic λ FIX II
library (Stratagene) and corresponding to the region from intron 1
to intron 3 of mouse ctbs gene was cloned in pBlueScript SK
(Stratagene). A BamHI site was created into exon 2 by site directedmutagenesis. This site was used to subclone the NEO gene from
pBSK-NEO vector. Orientation of this fragment was conﬁrmed by re-
striction analysis. The entire cassette was sequenced.2.2. Generation of chitobiase knockout mice
200 micrograms of the targeting vector were linearized with NotI
and introduced into 3×107 HM-1 murine embryonic stem (ES) cells
[15] by electroporation (Bio-Rad Gene Pulser II; 0.8 kV, 3 μF). The ES
cells were maintained on feeder layers under the selective pressure
of G418 containing medium (Sigma-Aldrich) for 8 days. ES cell clones
were picked, expanded and screened by PCR for homologous recom-
bination. Targeted clones were reconﬁrmed by Southern blot analysis
after digestion with EcoRI and hybridization with a 5’ external probe.
ES cells from two targeted clones were microinjected into blastocysts
from C57BL/6 N (Charles River) mice and transferred to pseudopreg-
nant recipient females. A total of 10 chimerae were born, with a high
contribution of agouti coat colour. The chimeric animals were bred
with C57BL/6 N mice, and agouti pups were screened for germ line
transmission of the mutant allele. The genotypes of the offspring of
these matings and all subsequent offspring were determined by PCR
on DNA from tail biopsy specimens.
The following primers were used: ctbsFOR (primer F in Fig. 1), 5′-
ATGACTGGTCACAGATTACAACTG-3′; ctbsREV (primer R), 5′-ATGGTG
ATCAACAAGGATGAGTATC-3′; NEOREV (primer N), 5′-ACTTCGCCCA
ATAGCAGCCAG-3′. PCR conditions were the following: denaturation
98 °C for 3 min, followed by 35 cycles of 30 sec at 98 °C, 30 sec at 64 °C
and 90 sec at 72 °C. The PCR resulted in fragments of 2700 bp for the
wild-type and 3200 bp for the mutant fragment.
Mice used in this study were housed under standard conditions in a
12-h light–dark cycle with food and water ad libitum. All experiments
were carried out in accordance with local and state regulations for
research with animals.
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Liver and kidney of WT and KO mice were homogenized in 50 mM
phosphate buffer pH 7.0 containing 150 mM sodium chloride (l:5, w/v)
and centrifuged at 15,000 ×g for 20 min. The supernatant was centri-
fuged a second time at the same conditions and passed through a syringe
packed with glass wool. The ﬂowthrough was centrifuged at 15,000 ×g
for 10 min. All centrifugation steps were performed at 4 °C. The ﬁnal su-
pernatant was applied to a 1.5×66-cm ACA-44 (LKB) gel ﬁltration col-
umn equilibrated with 50 mM phosphate buffer (pH 7.0) containing
150 mM sodium chloride and resolved at a ﬂow rate of 0.66 ml/min.
1 ml fractions were collected for determination of β-hexosaminidase
(β-Hex) and chitobiase activity.
2.4. β-Hexosaminidase, α-mannosidase, β-glucosidase and
chitobiase assay
β-Hexosaminidase andα-mannosidase activitywasmeasured using
3 mM 4-Methylumbelliferyl N-acetyl-β-D-glucosaminide (MUG)
(Toronto Research Chemicals) and 3 mM 4-Methylumbelliferyl α-D-
mannopyranoside (Sigma-Aldrich), respectively, in 0.1 M citric acid/
0.2 M disodium phosphate buffer (pH 4.5). β-glucosidase wasmeasured
using 3 mM4-Methylumbelliferyl β-D-glucopyranoside (Sigma-Aldrich)
in 0.1 M citric acid/0.2 M disodium phosphate buffer (pH 5.0) with 0.2%
taurodeoxycholic acid. The ﬂuorescence of the liberated 4-
methylumbelliferone was measured using a PerkinElmer LS B50 ﬂuo-
rimeter (λexcitation=360 nm; λemission=446 nm). One unit is the
amount of enzyme that hydrolyses 1 μmol of substrate in 1 min at 37 °C.
Chitobiase activity was determined incubating 33 μl sample with
34 μl 10 mM chitobiose (Toronto Research Chemicals) in 0,1 M citrate
/0.2 M disodium phosphate buffer (pH 3.5). After an appropriate in-
cubation time at 37 °C, 33 μl 0.8 M potassium tetraborate pH 10.4
were added, the sample was heated 3 min at 100 °C and cooled in
ice. 1 ml p-dimethylaminobenzaldehyde (DMAB) (prepared by dissol-
ving 10 g DMAB in 100 ml glacial acetic acid containing 12.5% (v/v)
10 N HCl and diluting this reagent 1:10 in acetic acid shortly before use)
were added and the reaction was conducted for 10 min at 37 °C. Samples
were cooled in ice and the amount of liberated N-acetylglucosamine
was determined using a spectrophotometer (λAbs=585 nm). One unit
is the amount of enzyme that hydrolyses 1 μmol of substrate in 1 min
at 37 °C.
2.5. Real time PCR
Real time PCRwas used to quantifymRNA for β-Hex,α-mannosidase
and β-glucosidase genes expressed by WT and KO 40-week-old mice
tissues using eukaryotic 18S rRNA as an endogenous control gene.
Pre-designed TaqMan® Gene expression assays were purchased by Ap-
plied Biosystems (primer probe set IDs: β-Hex Mm01282432_m1;
α-mannosidase Mm00487585_m1; β-glucosidase Mm00484700_m1;
18S Hs99999901_s1) and a 7300 Real-Time PCR System (Applied Bio-
systems) was used according to the manufacturer's instructions.
Threshold cycle (Ct) data for target and control genes were used to cal-
culate ΔCt values [ΔCt=Ct (target gene)−Ct (18 s RNA)]. Then, ΔΔCt
values were calculated [ΔΔCt=ΔCt (KO tissue)−ΔCt (WT tissue)].
The expression fold change was calculated as 2−ΔΔCt.
2.6. Production of an anti-CTBS polyclonal antibody
A GST-Ctbs fusion protein was obtained by cloning a 201 bp frag-
ment, corresponding to bases from 327 to 528 of murine Ctbs cDNA,
into pGEX-4T-1 plasmid (Amersham Biosciences). BL21 E. coli cells
were transformed with this pGEX-Ctbs plasmid and the recombinant
protein was puriﬁed by using Glutathione Sepharose 4B (Amersham
Biosciences), following the manufacturer's protocol. Two New
Zealand white rabbits (Charles River) were immunized with thepuriﬁed GST-CTBS protein to raise the anti-CTBS polyclonal antibody.
The rabbits were injected with a mixture of 500 μg of puriﬁed protein
mixed with an equal volume of complete Freund's adjuvant. The im-
munization was repeated twice with 200 μg protein, after 2 weeks
from the precedent injection. 10 days after the ﬁnal injection, antise-
rum was harvested from the carotid artery and stored at−80 °C. An-
tibody was puriﬁed by dilution in blocking buffer (TBS with
0.1%Tween, 5% non fat milk) and O/N incubation on a nitrocellulose
strip where GST-Ctbs had been blotted. After 3 washes in TBS-
Tween, antibody was eluted in 100 mM glycine buffer, pH 3.5. pH
was immediately neutralized with 0.2 M Na2HPO4.
2.7. Histology
Mice were killed by an overdose of anaesthetics and ﬁxed by se-
quential transcardiac perfusion with phosphate buffer w/ 1% procaine
followed by either 6% glutaraldehyde or a modiﬁed Bouin's solution,
the latter corresponding to the standard Bouin mixture diluted 1:3
in Dulbecco PBS.
(Tissues were ﬁxed o/n in the same solutions and in the case of
Bouin ﬁxation stored in 1% neutral buffered formaline.)
For immunohistochemistry and lectin histochemistry, tissues from
modiﬁed Bouin-ﬁxed mice were either embedded in low-melting-
point parafﬁne wax and sectioned at 7 μm or (to avoid extraction by
organic solvents during embedding) were directly cut on a vibratome
at 20 μm.
For transmission electron microscopy, glutaraldehyde-ﬁxed tissues
were postﬁxed in 2% osmium tetroxide, dehydrated and embedded in
Spurr'smediumafter passage through propylene oxide as an intermedi-
ate. Blockswere semithin sectioned at 1 μm for high resolution lightmi-
croscopy after staining with either toluidine blue/pyronine G or the
lipid-selective p-phenylenediamine, trimmed to regions of interest
and were then recut at 70 nm for TEM, TEM sections were contrasted
with lead citrate/uranyl acetate prior to evaluation. Light microscopy
images were recorded on a Nikon 90i photomicroscope.
2.8. Lipid analysis of kidney
Lipids were extracted from kidneys and analyzed as previously de-
scribed [16]. An aliquot of the total lipid extract was hydrolyzed
under alkaline conditions to remove phospholipids. This was done
to allow the quantiﬁcation of sphingolipids. To detect a possible accu-
mulation of phospholipids or sphingolipids total lipids and alkali-
stable lipids, respectively, were analyzed separately on the same
plate by TLC using reference standards. Separated lipids were visual-
ized according to Yao and Rastetter [17] and quantiﬁed by densitom-
etry scanning [16].
2.9. Extraction of soluble oligosaccharides
A sample of the various tissues originating fromWT and chitobiase
KOmice were homogenized in an ice-cold KMH buffer (110 mMpotas-
siumacetate, 2 mMmagnesium acetate, 20 mMHepes, pH 7.2) contain-
ing a protease inhibitor cocktail (complete, Roche Diagnostics) by using
a Potter–Elvehjem homogenizer (750 rpm; ﬁve strokes). The cellular
homogenate was then submitted to lipid extraction by addition of
3 ml of CHCl3/MeOH/H2O (3/2/1, v/v/v) (Kmiecik et al., 1995) [18].
The aqueous phase resulting from the lipid extraction was then
lyophilized.
2.10. α-mannosidase digestions
Alpha-mannosidase digestions were carried out using the follow-
ing conditions : jack bean α-mannosidase (EC 3.2.1.24, Sigma Aldrich),
0.5 U of enzyme in 200 μl 50 mM ammonium acetate buffer pH 4.5;
α1,2 mannosidase (EC 3.2.1.113, isolated from Aspergillus saitoi,
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5. Enzyme digestions were incubated at 37 °C for 48 h with a fresh
aliquot of enzyme added after 24 h and terminated by boiling for
10 min before lyophilization. Samples were then permethylated for
MALDI-MS and GC-MS analysis.2.11. Permethylation of free oligosaccharides and disaccharide standard
Permethylation of the freeze-dried oligosaccharides and sample
clean-up were performed as described [19]. Internal standards
(Galβ1,4GlcNAc)and (Fuc α1,2 Galβ1,4GlcNAc)were permethylated
under the same conditions.2.12. MALDI TOF-MS analysis
For each tissue sample, permethylated oligosaccharides weremixed
with a knownamount of permethylated standard disaccharide (Galβ1,4
GlcNAc). For urine samples, the standard was the permethylated Fuc
α1,2 Galβ1,4GlcNAc). Total permethylated oligosaccharides were
cocrystallized with 2,5-dihydroxybenzoic acid as matrix (10 mg/ml
2,5-dihydroxybenzoic acid in methanol/water solution (50/50)) and
freeze-dried.
MALDI-TOF-MS experiments were carried out on a Voyager Elite
DE-STR Pro instrument (PerSeptive Biosystems, Framingham, MA)
equipped with a pulsed nitrogen laser (337 nm) and a gridless
delayed extraction ion source. The spectrometer was operated in
the positive reﬂectron mode by delayed extraction with an accelerat-
ing voltage of 20 kV, a pulse delay time of 250 ns, and a grid voltage of
72%. All spectra represent accumulated spectra obtained by 500 laser
shots. For each condition, three samples were spotted and the
amount of each oligosaccharide was relatively quantiﬁed and esti-
mated by calculating the ratio between the relative amount of these
oligosaccharides and the internal standard in the MALDI-MS spectra.
Protein concentration of each tissue sample was measured by a
micro BCA Protein assay reagent kit (Pierce).Fig. 2. Evidence of chitobiase deﬁciency. (A) Speciﬁc activity in 10-week-old wild type (whi
MUG and chitobiose. Chitobiase is expressed at high levels in liver and kidney, while heart
resent one standard deviation of three WT and three KO tissues. (B) Gel ﬁltration of wild typ
1.5×66-cm ACA-44 LKB gel ﬁltration column. MUG (ﬁlled circles) and chitobiose (empty c
activity, absent in KO tissues. (C) Immunoblot analysis of chitobiase in liver extracts. Tota
and immunoblotted with anti-chitobiase antibody. β-actin was used as a loading control.2.13. Linkage analysis and GC/MS analysis
The permethylated free oligosaccharides were hydrolyzed in
300 μl of 4 M TFA at 100 °C for 4 h. After removing TFA by drying in
vacuo, the permethylated compounds were then reduced at room
temperature overnight by adding 300 μl of 2 M ammonia solution
containing sodium borodeuteride (10 mg/ml). The reduction was ter-
minated by adding acetic acid, and borates were eliminated under a
stream of nitrogen in the presence of methanol containing 5% (v/v)
acetic acid. After adding 50 μl of pyridine and 200 μl of acetic anhy-
dride, peracetylation was carried out at 100 °C for 2 h. After evapora-
tion under a stream of nitrogen, the partially methylated alditol
acetates (PMAAs) were dissolved in chloroform, and the chloroform
phase was washed 7 times with water. This PMAA-containing phase
was ﬁnally dried under a stream of nitrogen, and the PMAAs were dis-
solved in acetonitrile before GC-MS analysis. GC separation of PMAAs
was performed using a Carbo Erba GC 8000 gas chromatograph ﬁtted
with a 25-m–0.32-mm CP-Sil5 CB low bleed capillary column, 0.25-m
ﬁlm phase (Chrompack France, Les Ullis, France). The temperature of
the Ross injector was 260 °C. Samples were analyzed using a temper-
ature program starting by a gradient of 2 °C/ min from 130 to 180 °C
after 2 min at 130 °C followed by a gradient of 4 °C/min until 240 °C.
The column was coupled to a Finnigan Automass II mass spectrome-
ter. PMAA analyses were performed in the electron impact mode
using an ionization energy of 70 eV. Relative abundance of the various
PMAA derivatives was carried out using total ion current of the MS
detector in the positive ion mode.3. Results
3.1. Generation of Ctbs-deﬁcient mice
We generated a null allele of the Ctbs gene by homologous recom-
bination in embryonic stem (ES) cells. The targeting construct
inserted the coding sequence of the neomycin resistance gene
(NEO) in exon 2 of the Ctbs gene (Fig. 1, panel B).te bars) and Ctbs-deﬁcient (black bars) liver, kidney and heart towards two substrates,
is representative of tissues where chitobiase is expressed at low levels. Error bars rep-
e (WT) and chitobiase-deﬁcient (KO) liver and kidney. Tissue extracts were applied to a
ircles) were used as substrates. Arrows indicate the peak corresponding to chitobiase
l lysates from liver of wild type and Ctbs deﬁcient mice were resolved by SDS-PAGE
Fig. 3. β-hexosaminidase, α-mannosidase and β-glucosidase enzyme activity and gene
expression assay. (A) Three wild type (white bars) and three homozygous mutant mice
(black bars) were analyzed at the age of 40 weeks. Error bars represent one standard
deviation. β-hexosaminidase activity increased in assayed tissues of knockout mice
when compared with wild type. Asterisks indicate a signiﬁcant difference (Pb0.05).
In liver, kidney and lung, but not brain, α-mannosidase showed a tendency for higher
activity in KO mice compared to wild type control. β-glucosidase activity showed no
difference between mutant and wild type mice. (B) β-hexosaminidase (black bars),
α-mannosidase (white bars) and β-glucosidase (gray bars) expression fold changes
in 40-week-old KO mouse tissues over WT control tissues. Two KO and two WT mice
were used for the analysis, each assay was run in triplicate. The differences in expres-
sion levels are consistent with the activity proﬁles.
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homologous recombination. Subsequent Southern blot analysis of
EcoRI digested genomic DNA conﬁrmed the disruption of the Ctbs
gene for all of these clones. The 525-bp 5’ ﬂanking probe detected a
6.1 kb EcoRI fragment of the wild-type allele, and a 5.0 kb speciﬁc
fragment of the targeted allele. Two targeted ES cell clones were cho-
sen for injection into C57BL/6 blastocysts. Male chimeras with high
contribution of agouti colour suggesting germ line transmission of
the disrupted Ctbs allele were mated with wild type females. As
expected, 50% of the F1 mice were heterozygous for the NEO inser-
tion. In order to generate Ctbs−/− mice, heterozygous mice were
crossed and the genotype of offspring was determined by Southern
blot analysis (Fig. 1, panel C). For rapid genotyping of mice a PCR
was designed in which the wild-type allele yielded a 2.7 kb fragment
and the disrupted Ctbs allele a 3.2 kb fragment. (see Fig. 1, panel D).
Because Ctbs is abundantly expressed in kidney [14], total RNA
was isolated from kidneys of wild-type (+/+), and homozygous
Ctbs-deﬁcient (−/−) mice. As expected, Ctbs mRNA was expressed
in wild-type mice and absent in Ctbs-deﬁcient mice (Fig. 1, panel E).
3.2. Enzyme activity
di-N-acetylchitobiose is commonly used as a substrate to quantify
chitobiase activity. However, at least one other lysosomal enzyme, β-
Hex, is able to hydrolyze this disaccharide [2]. This glycosidase can be
distinguished from chitobiase due to its ability to hydrolyze the ﬂuo-
rimetric substrate 4-Methylumbelliferyl-N-acetyl-β-D-glucosaminide
(MUG). Homozygous mutant mice were assayed and compared to
wild-type animals at the age of 10 weeks. In tissues with high Ctbs
expression levels, like liver and kidney [14], the measured activity to-
wards chitobiose was reduced to roughly 50% in KO mice. The MUG
activity, however, remained unaltered, suggesting that β-Hex was
not the involved enzyme (Fig. 2, panel A). In tissues, like heart,
where chitobiase is expressed at low levels, activity in KO mice was
similar to that in WT ones. In order to separate chitobiase from β-
Hex, a gel ﬁltration was carried out, as described in Materials and
Methods. Two β-Hex peaks were obtained, probably due to the two
forms β-Hex B and β-Hex A with molecular masses of 130KDa and
120KDa respectively. Chitobiase, molecular weight 43 kDa [5], eluted
after β-Hex, as expected. In KO tissues, the peak corresponding to
chitobiase was completely absent, conﬁrming the loss of chitobiase
expression (Fig. 2, panel B).
Interestingly, the elution proﬁle for chitobiase showed an addi-
tional peak lacking activity towards the synthetic substrate, indicat-
ing the presence of an additional enzyme able to hydrolyze the
disaccharide at acidic pH with a molecular weight greater than that
of β-Hex.
The β-Hex activity was assayed again at the age of 40 weeks, to-
gether with those of α-mannosidase and β-glucosidase. β-Hex activ-
ities were signiﬁcantly increased in the mutant when compared with
the wild-type tissues, whereas α-mannosidase showed a tendency
for elevation (except brain) and the β-glucosidase activity was simi-
lar in KO and wild type mice (Fig. 3, panel A). Real-time PCR analysis
showed increased expression levels of β-Hex and, to a minor extent,
α-mannosidase in KO tissues, whereas β-glucosidase mRNA resulted
unchanged (Fig. 3, panel B).
3.3. Immunoblotting
Western blot analysis using a polyclonal anti-chitobiase antibody,
obtained as described in Materials and methods, revealed a signal
corresponding to chitobiase in liver and kidney of normal mouse,
while in deﬁcient tissues no speciﬁc bands were detected, conﬁrming
that the expression of the protein was completely abolished. In Fig. 2
panel C a representative Western blot of liver is shown.3.4. Pathological ﬁndings in organs
The most obvious changes in CTBS−/− mice were seen even in
light microscopy in the kidney, where intensely stained storage mate-
rial was found (Fig. 4) in a scattered subpopulation of epithelial cells
exclusively of proximal tubules situated deep in the cortex. The ex-
tent and severity of storage was highly variable, ranging from minute
dots barely visible in oil immersion up to conglomerates ﬁlling the
major part of an epithelial cell. In a subfraction of tubules, entire epi-
thelial cells as well as cellular debris were seen to ﬁll the tubule
Fig. 4. Kidney involvement in Ctbs deﬁciency. (A, B) Low-power micrographs of WT (A) and KO (B) kidney indicate the presence of dark inclusion bodies (arrows in B) in a subset of
proximal tubules. At higher magniﬁcation (WT shown in C, KO in D–E) it can be shown that this material can reside within epithelial cells themselves (arrows in D) at sometimes
spectacular sizes (E) or even ﬁll the tubule lumen, probably after disintegration of affected cells (PT in E). Even at medium magniﬁcation, a lamellar structure of the stored material
can sometimes be discerned (arrows in F). Low-power electron microscopy clearly indicates that small inclusion bodies (white arrows in G) are lined up at the basis of the microvilli
(MV), while larger accumulations of stored material typically reside deeper within the cells. Higher magniﬁcation reveals a multilamellar, onion shell-like substructure of already
these smaller aggregates, apparently surrounded by a somewhat detached outer membrane. Medium-sized inclusion (diameter approx. 0.5 μm, I) may also be surrounded by a ho-
mogenous matrix within a membrane-bound compartment.. Larger inclusions (J–L; L representing an enlargement of the white box in K) are characterized by a densely packed
multilamellar structure, often surrounding a strongly contrasting amorphous core, indicative of at least a major contribution of polar lipids to the stored material. Scale bars
300 μm in A and B, 30 μm in C and F, 15 μm in D and E; 7 μm in G, 50 nm in H, 300 nm in I–K, and 100 nm in L.
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with the lipid-selective dye p-phenylene diamine, pointing towards
a signiﬁcant amount of lipids enclosed here.
In TEM, it was striking that the intensely contrasted storage mate-
rial was often organized in multilamellar myelin ﬁgures, again point-
ing towards a major content of (polar) lipids. Moreover, we often
observed an intracellular gradient within the affected cells, with
very small inclusion bodies lined up immediately below the actin net-
work underlying the microvilli, and larger conglomerates deeper
within the cell, which could be interpreted as an origin of stored ma-
terial linked to the resorptive capacity of these cells.After the initial observation of storage material developing in as-
sociation with brush borders and thus with epithelia performing
high-capacity resorption of material from a lumen, cells with a similar
differentiation and function like intestinal epithelia were investigated
in detail. However, epithelia of the proximal kidney tubule remained
the sole cell type affected by this type of storage.
Lectin screening using chitobiase-binding lectins did not reveal
differences between WT and KO kidney, only with lectins against
mannosyl compounds a generalized staining of the apical half of
proximal tubule epithelial cells was observed in KO and was absent
in WT mice, which could indicate that the scattered storage seen in
Fig. 5. Hematoxylin–eosoin-stained liver sections of WT (A) and Ctbs KO (B, c, d) mice showing central veins (CV) and surrounding liver lobules. Note the occurrence of multiple
enlarged Kupffer cells ﬁlled with strongly pigmented phagocytosed material in KO tissue (shown in enlarged detail in c and d).
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has caused decompensation on the cell biological level (data not
shown).Fig. 6. MALDI TOF analysis of oligosaccharides after α-mannosidase treatments. Permethyla
lyzed by MALDI TOF after treatment with jack bean α-mannosidase or saitoi α-mannosidase
α-mannosidase.A less constant effect of CTBS deﬁciency was seen in liver, where a
subpopulation of vesiculated Kupffer cells presented with increased
size (Fig. 5).ted oligosaccharides extracted from wild type (WT) and chitobiase KO liver were ana-
. (A), control; (B), treatment with jack bean α-mannosidase; (C), treatment with saitoi
Fig. 7. Quantitative analysis of accumulated Man2GlcNAc2 (A) and Man3GlcNAc2 (B) in
chitobiase KO mice tissues. After extraction from wild-type (white bars) and chitobiase
KO (black bars) mouse tissues, soluble oligosaccharides were permethylated and mixed
with a permethylated standard. Quantiﬁcation of oligosaccharides was performed by cal-
culating the ratio of peak height taking the oligosaccharide standard as reference. The
values were normalized to the quantity of proteins in mg. For all assays, values are
means±SD of three independent experiments.
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tigated by TLC analysis. However, no quantitative or qualitative differ-
ences between the lipid proﬁles of wild type and CTBS knockout
tissues were evident (data not shown). However, this negative result
could be due to sensitivity problems, as only a restricted number of
proximal tubules is affected in each KO mouse.
3.5. Structural analyses of accumulated oligosaccharides in chitobiase KO
mice tissues
To obtain functional evidence of the consequences of knock-
out chitobiase expression, structural analysis of free oligosaccha-
rides was performed in liver and kidney of KO and WT mice.
Free oligosaccharides were extracted from cellular homogenates
and permethylated prior to analysis by MALDI-TOF MS. While in
WT tissues a series of oligosaccharides representing Man2–6GlcNAc1,
essentially originating from the endoplasmic reticulum-associated pro-
tein degradation (ERAD) process, were detected, in KO tissues two
major oligosaccharides were observed (in Fig. 6 the spectrum obtained
from liver is shown. Similar results have been obtained from kidney,
data not shown). According to theirm/z ratio, 967 and 1171, monosac-
charide composition in terms of Hex and HexNAc have been deter-
mined as Hex2HexNAc2 and Hex3HexNAc2, respectively. Based on
GC-MS data these oligosaccharides have been assigned to Man2-
GlcNAc2 and Man3GlcNAc2, respectively.
Linkage analyses on Man2GlcNAc2 oligosaccharides were per-
formed by GC-MS. Results expressed in Table 1 are fully consistent
with the presence of a major Manα1–6Manβ1–4GlcNAcβ1–4GlcNAc
oligosaccharide and, in lower concentration, of the tri-mannosyl core
(Manα1–3[Manα1–6]Manβ1–4GlcNAcβ1–4GlcNAc) oligosaccharide.
To conﬁrm the linkage results, oligosaccharides from WT and KO
tissues were treated with jack beanα-mannosidase, able to hydrolyze
α1–2, α1–3 and α1–6 linkages, or α-mannosidase from Aspergillus
saitoi, speciﬁc for α1–2 linkage. After jack bean α-mannosidase treat-
ment of KO samples, the molecular ion at m/z 1171 (Hex3HexNAc2)
was abolished and the one corresponding tom/z 967 (Hex2HexNAc2)
was signiﬁcantly decreased with an increasing appearance of a signal
consistent with the core of N-glycans Hex1HexNAc2 (m/z 763). In
contrast, after treatment with α-mannosidase from Aspergillus saitoi
molecular ions at m/z 1171 and 967 remained intact (Fig. 6). A
major peak corresponding to Manβ1–4GlcNAc appears in WT jack
bean α-mannosidase treated oligosaccharides, while the peak consis-
tent with Man3GlcNAc1 species was predominant after α1–2 speciﬁc
mannosidase treatment.
3.6. Quantitative analysis of accumulated Man2GlcNAc2
and Man3GlcNAc2
Quantiﬁcation of accumulated oligosaccharides was performed by
using a semi-quantitative experiment using the isotopic permethyla-
tion of an internal standard with 13CH3I as previously described [20].
As observed in Fig. 7, Manα1–6Manβ1–4GlcNAcβ1–4GlcNAc oligo-
saccharide was signiﬁcantly increased in all KO mouse tissues and
particularly in liver. Even if the accumulation of the tri-mannosylTable 1
GC Linkage analysis of partially methylated alditol acetates derivatives of Hex2Hex-
NAc2 and Hex3HexNAc2 oligosaccharides accumulated in KO mice tissues.
Retention
time (min)
Characteristic fragment ions Assignment Relative
abundance
21.12 102, 118, 129, 145, 161, 162, 205 Terminal mannose 0.46
27.03a 102, 118, 129, 162, 189, 233 6-Linked mannose 0.46
36.21 117, 159, 233 4-Linked GlcNAc 1.00
31.24b 118, 129, 189, 234 3,6-Linked mannose 0.10
a Signals signiﬁcantly decreased after treatment with jack bean α-mannosidase.
b Signals not observed after treatment with jack bean α-mannosidase.core (Manα1–3[Manα1–6]Manβ1–4GlcNAcβ1–4GlcNAc) oligosac-
charide was less, its presence is observed in all tissues with a predom-
inant appearance in lung and brain.3.7. Analyses of oligosaccharides in urines
Urine of Ctbs KO mice was analyzed in order to detect the pres-
ence of the oligosaccharides accumulated in the tissues. Man2-
GlcNAc2 concentration in KO urines is up to 10-fold higher than
WT. The presence of Man3GlcNAc2 was observed at low levels inFig. 8. Quantitative analysis of accumulated Man2GlcNAc2 (gray bars) and Man3-
GlcNAc2 (black bars) in chitobiase KO mice urines. Soluble oligosaccharides were per-
methylated and mixed with a permethylated standard and were analyzed by MALDI
TOF. Quantiﬁcation of oligosaccharides was performed by calculating the ratio of
peak height taking the known amount of oligosaccharide standard as reference. For
all assays, values are means±SD of three independent experiments. Man3GlcNAc2
species was not detected in wild type mice urines (nd: not detected).
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(Fig. 8).
4. Discussion
During the degradation of glycoproteins in lysosomes, the differ-
ent glycosidic linkages in N-linked glycans are hydrolyzed by highly
speciﬁc glycosidases, following a highly ordered pathway. Therefore
a defect in a single enzyme will result in the accumulation of its sub-
strate, causing a lysosomal storage disease [21]. A speciﬁc known
storage disorder is associated to each of the enzyme participating at
the N-linked glycan catabolism. The only exceptions are represented
by chitobiase and core speciﬁc α1–6mannosidase, as corresponding
lysosomal diseases have not been identiﬁed to date.
We have generated chitobiase KOmouse lines by gene targeting. A
polyclonal anti-chitobiase rabbit antibody was used to demonstrate
that immunoreactivity for chitobiase was absent in tissues of knock-
out mice. Gel ﬁltration chromatography conﬁrmed that there was
no chitobiase activity in such tissues.
Chitobiase KOmice are fertile and have a normal appearance up to
1 year of age. Nevertheless, they present pathological features com-
mon to other animal models of lysosomal disorders: accumulation
of oligosaccharides was present in all organs investigated which are
liver, kidney, lung, spleen, heart and brain (staining with lectins spe-
ciﬁc for mannose residues conﬁrmed the presence of mannose-
containing oligosaccharides in all tested tissues) and the stored oligo-
saccharides are also excreted into urines at high levels; histological
analysis revealed the presence of enlarged Kupffer cells in liver, al-
ready described in α-mannosidase- [22] and β-hexosaminidase B-
deﬁcient mice [23]; storage material accumulations in kidney proxi-
mal tubule epithelial cells resemble the membranous cytoplasmic
bodies typical of GM2 gangliosidosis and are thus suggestive of polar
lipids [24]. We could, however, not conﬁrm lipid storage by biochem-
ical methods.
While we could show accumulation of oligosaccharides in all tis-
sues examined, we have evidence for the development of distinct
storage material assemblies only for kidney and hepatic Kupffer
cells. In kidney, surprisingly, only a small subset of proximal tubule
epithelia develop the pathologic changes described above, pointing
towards some still unexplained selectivity in cellular uptake, like spe-
ciﬁc receptors. Alternatively, storing cells could represent only early
decompensating cells, which would be followed by a more systemic
kidney damage at higher age. In any case, the situation seems to be
strikingly different from glycolipid storage e.g. in Fabry disease, in
which several renal cell types are affected in parallel.
Thus, if one assumes that the chitobiase KO mice resemble a so far
unidentiﬁed human disease the possible human phenotype could be a
purely renal disease. Alternatively, the accumulation of oligosaccha-
rides without detectable storage material in other tissues could
point to a late onset disease in which the accumulation has to proceed
for some time before it manifests as microscopically visible storage
material. This could result in a late onset disease with e.g. neurologic,
renal and cardiac dysfunction.
The genetic lack of one lysosomal enzyme often leads to the in-
crease of activities of the other enzymes in the same catabolic path-
way, as happens in β-mannosidase knockout mice [25] and in
caprine beta-mannosidosis [26]. We assayed β-hexosaminidase and
α-mannosidase activity in 10 weeks and 40 weeks old chitobiase-
deﬁcient mice. At young age, there was no difference between normal
and mutant tissues, whereas at older age β-hexosaminidase activity
was statistically signiﬁcantly increased in all tested tissues. Likewise
α-mannosidase activity appeared higher in liver, kidney and lung
from chitobiase-deﬁcient mice than normal controls. β-glucosidase,
an enzyme not involved in the N-linked glycoprotein degradation
pathway, as expected had similar activity in mutant and wild type
mice. The increase of β-hexosaminidase and α-mannosidase activityis due to a higher expression of the genes encoding for these hydro-
lases, suggesting the involvement of a cellular mechanism as a re-
sponse to a stress condition. The enzymatic ﬁndings further indicate
that the disruption of the Ctbs gene causes biochemical changes sim-
ilar to other mouse models for lysosomal storage disorders.
Chitobiase and core speciﬁc α1–6mannosidase are differently
expressed in tissues of various mammals. In ruminants, felines and
dogs, expressing low levels of these enzymes, the classical α-
mannosidase cleaves the α1–6 mannosidic linkage of the glycan
core and the digestion of the chitobiose core is completed by the ac-
tion of the β-hexosaminidase from the nonreducing end. In humans
and rodents the trimming of α1–6 linked mannose of the glycan
core is totally impaired if the chitobiose linkage is intact [7]. The N-
acetylglucosamine at the reducing end is ﬁrst removed by the chito-
biase, and only subsequently the core speciﬁc α1–6 mannosidase
cleaves the mannosidic linkage at the nonreducing end.
Therefore, the accumulation of Manα1–6Manβ1–4GlcNAcβ1–4-
GlcNAc observed in chitobiase-KO mice is in accordance with previ-
ous studies. In contrast, the presence of stored Manα1–3[Manα1–6]
Manβ1–4GlcNAcβ1–4GlcNAc, even if to a minor extent, is not easily
explainable. In fact, α-mannosidase is known to cleave the α1–3
mannosidic linkage, regardless of the structure at the reducing end
of the oligosaccharide. However, the similarity of chitobiase and
α1–6 mannosidase expression pattern in humans and rodents sug-
gests that human subjects lacking chitobiase activity should accumu-
late the same material observed in knockout mice, and consequently
present similar pathological features.
Patients affected by beta-mannosidosis, a storage disorder caused
by beta-mannosidase deﬁciency, show accumulation of the disaccha-
ride Manβ1–4GlcNAc, and present a mild heterogeneous clinical ex-
pression [27]. Mental retardation, dysmorphology, developmental
delay and hearing loss are the most common symptoms [28–30]. Ru-
minants affected by the same pathology accumulate the trisaccharide
Manβ1–4GlcNAcβ1–4GlcNAc, due to chitobiase deﬁciency. Affected
animals have a severe phenotype, with features that include inability
to stand, facial dysmorphism, intention tremors, digital joint hyperex-
tension [31] and most cases do not survive to the neonatal period. Al-
though a strict correlation between the length of the stored product
and the severity of the pathology has not been clearly demonstrated,
an accumulation of a tetrasaccharide should lead to the onset of a
more severe disorder as compared to the phenotype seen in beta-
mannosidosis. This hypothesis is supported by the observation that
aspartylglycosaminuria, characterized by the lysosomal accumulation
of Manα1–6Manβ1–4GlcNAcβ1–4GlcNAc-Asn, even if this is not the
only stored molecule, is a progressive and ultimately fatal disease
[32].
Recent studies revealed a high prevalence of lysosomal storage
disorders among symptomatically treated patients with unclear diag-
nosis. Fabry disease, an X-linked lysosomal disease caused by the de-
ﬁciency of the glycohydrolase α-galactosidase A, is a striking
example: a study on the frequency of unrecognised Fabry disease in
a group of 721 patients suffering from acute cryptogenic stroke point-
ed out that the 4.9% of male patients and the 2.4% of women had a bi-
ologically signiﬁcant mutation within the α-galactosidase A gene
[33]. Similar screenings identiﬁed previously undiagnosed Fabry dis-
ease in 1%–4% of patients with hypertrophic cardiomyopathy [34,35]
and in 0.36%–1.2% of males receiving hemodialysis [36,37].4.1. Conclusions
The pathological features of chitobiase-deﬁcient mice described in
this work demonstrate in vivo that the complete breakdown of N-
linked oligosaccharides in lysosomes requires the action of chitobiase,
despite the presence of other enzymes able to hydrolyze the chito-
biose core, like β-hexosaminidase. Moreover, the accumulation of
1146 E. Persichetti et al. / Biochimica et Biophysica Acta 1822 (2012) 1137–1146an unpredicted glycan structure (Man3GlcNAc2) opens new perspec-
tives in studying the oligosaccharides degradating pathway.
The recent ﬁndings on the actual rate of lysosomal diseases in in-
completely diagnosed patients under treatment, suggest that a genetic
defect of the chitobiase should be the cause of a not yet described lyso-
somal storage disease and affected patients could be already in therapy
without a complete diagnosis. The in-depth characterization of the chit-
obiase knockoutmousemodelwill provide a precise panel of symptoms
for the identiﬁcation of such patients. Preliminary data from the mouse
model may indicate that this putative disease would be milder and/or
clinically present at higher ages than gangliosidoses and may not have
major neurological symptoms. A genomic screening formutations/dele-
tions in the chitobiase gene on subjectswith comparable symptoms and
an incomplete diagnosis could identify chitobiase-deﬁcient patients.Acknowledgements
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